Celldex Therapeutics, Inc. Debt Securities, Available-for-sale, Amortized Cost
Celldex Therapeutics, Inc. (CLDX) had Debt Securities, Available-for-sale, Amortized Cost of $671.43 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $671.43M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $415.80M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $488.67M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $546.02M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $671.43M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $415.80M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $488.67M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $546.02M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $606.55M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $655.18M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $696.21M 10-K · filed 2026-02-25 |
| 2024-09-30 | $716.91M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $760.39M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $709.12M 10-Q · filed 2024-05-06 |
| 2023-12-31 | $388.07M 10-K · filed 2025-02-27 |
| 2023-09-30 | $214.68M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $225.00M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $224.74M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $276.86M 10-K · filed 2024-02-26 |
| 2022-09-30 | $307.60M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $331.43M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $357.66M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $369.81M 10-K · filed 2023-02-28 |
| 2021-09-30 | $350.95M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $120.59M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $106.78M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $150.59M 10-K · filed 2022-02-28 |
| 2020-09-30 | $181.43M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $138.89M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $31.00M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $53.13M 10-K · filed 2021-03-29 |
| 2019-09-30 | $56.29M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $61.56M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $53.53M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $69.72M 10-K · filed 2020-03-26 |
| 2018-09-30 | $72.81M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $70.12M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $83.46M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $99.17M 10-K · filed 2019-03-07 |
| 2017-09-30 | $85.80M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $87.84M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $124.56M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $147.37M 10-K · filed 2018-03-07 |
| 2016-09-30 | $171.49M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $187.52M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $190.90M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $218.07M 10-K · filed 2017-03-14 |
| 2015-09-30 | $237.85M 10-Q · filed 2015-11-05 |
| 2015-06-30 | $252.57M 10-Q · filed 2015-08-10 |
| 2015-03-31 | $237.58M 10-Q · filed 2015-04-29 |
| 2014-12-31 | $173.01M 10-K/A · filed 2016-02-25 |
| 2014-09-30 | $191.51M 10-Q · filed 2014-11-05 |
| 2013-12-31 | $133.50M 10-K · filed 2015-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |